← Back to all trials
Recruiting
NCT05602090
Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials
Conditions: Poor Ovarian Reserve
Sex: Female
Ages: 20 Years – 40 Years
Healthy volunteers: 1
Phase: PHASE2, PHASE3
Enrollment: 120
Sponsor: Beni-Suef University
Location: Egypt
Summary
Effect of Growth Hormone Adjuvant Therapy on ICSI Trials For Poor ovarian Reserve Patients
Eligibility Criteria
Inclusion Criteria:According to Bologna criteria at least two of the following features must be present:Advanced maternal age (40years).A previous poor ovarian response with 3 oocytes retrieved after conventional stimulationAn abnormal ovarian reserve test (ORT)antral follicle count (AFC)<7 oranti-Müllerian hormone (AMH)<1.1ng/ml.Exclusion Criteria:Any known contraindications to the approved fertility drugs.Any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment)4- Hydrosalpinx 5- Uterine malformations or abnormal uterine cavity.
6- Basal FSH more than 17 IU.
7- Abnormal karyotyping 8- Partner with severe male factor 9- Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism.
Source: ClinicalTrials.gov (NCT05602090). StuddyBuddy aggregates publicly available trial information.
